LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

NVO

65.43

-3.4%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

NVO

65.43

-3.4%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

NVO

65.43

-3.4%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

NVO

65.43

-3.4%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

NVO

65.43

-3.4%↓

Search

Essa Pharma Inc

Slēgts

1.67

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1.62

Max

1.69

Galvenie mērījumi

By Trading Economics

Ienākumi

2.2M

-6.4M

EPS

-0.195

Darbinieki

35

EBITDA

-2.2M

-8.5M

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-1.3M

75M

Iepriekšējā atvēršanas cena

1.67

Iepriekšējā slēgšanas cena

1.67

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

Essa Pharma Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 13. maijs 23:20 UTC

Peļņas

Aristocrat Leisure Boosts Half-Year Dividend, Keeps Focus on M&A

2025. g. 13. maijs 23:48 UTC

Tirgus saruna

Gold Edges Higher, Supported by Signs of Mild U.S. Inflation -- Market Talk

2025. g. 13. maijs 23:43 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 13. maijs 23:43 UTC

Tirgus saruna

Nikkei May Rise on Hopes for Improving U.S.-China Trade Relations -- Market Talk

2025. g. 13. maijs 23:24 UTC

Tirgus saruna
Peļņas

Global Equities Roundup: Market Talk

2025. g. 13. maijs 23:24 UTC

Tirgus saruna
Peļņas

Aristocrat's 1H Result Falls Short, Jefferies Says -- Market Talk

2025. g. 13. maijs 22:58 UTC

Peļņas

Table: Samsung Fire & Marine 1Q Consolidated Net KRW609.03B Vs KRW701.95B

2025. g. 13. maijs 22:58 UTC

Peļņas

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Net KRW609.03B Vs KRW701.95B

2025. g. 13. maijs 22:58 UTC

Peļņas

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Op Pft KRW792.36B Vs Op KRW897.06B

2025. g. 13. maijs 22:58 UTC

Peļņas

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Rev KRW6.106T Vs KRW5.507T

2025. g. 13. maijs 22:38 UTC

Peļņas

Aristocrat: Continues to Actively Pursue Strategic M&A Activities

2025. g. 13. maijs 22:38 UTC

Peļņas

Aristocrat: Remains Committed to Capital Management Strategy, Ongoing Share Buy-Back Program

2025. g. 13. maijs 22:37 UTC

Peļņas

Aristocrat: Expects More Operating Momentum in 2H Amid Product Rollout, Technology Initiatives

2025. g. 13. maijs 22:36 UTC

Peļņas

Aristocrat: Sees Accelerating Performance at Interactive Unit Toward FY 2029 US$1 Bln Revenue Target

2025. g. 13. maijs 22:35 UTC

Peļņas

Aristocrat: Expects Continued Market Share Gains from Gaming Unit

2025. g. 13. maijs 22:34 UTC

Peļņas

Aristocrat: Expects to Deliver NPATA Growth Over the Full Year on a Constant Currency Basis

2025. g. 13. maijs 22:33 UTC

Peļņas

Aristocrat: Interactive Business Delivered Strong Revenue Growth

2025. g. 13. maijs 22:33 UTC

Peļņas

Aristocrat: Gaming Unit Continued to Deliver Market Share Gains

2025. g. 13. maijs 22:33 UTC

Peļņas

Aristocrat: Product Madness' Key Social Casino Franchises Continued to Outperform

2025. g. 13. maijs 22:30 UTC

Peļņas

Aristocrat Interim Dividend 44 Australian Cents/Share

2025. g. 13. maijs 22:30 UTC

Peļņas

Aristocrat 1H Statutory Net Profit from Continuing Operations A$511 Mln, Down 21.6%

2025. g. 13. maijs 22:29 UTC

Peļņas

Aristocrat 1H Normalized Operating Revenue A$3 Bln, Up 8.7%

2025. g. 13. maijs 22:28 UTC

Peļņas

Aristocrat 1H Normalized Net Profit A$733 Mln, Up 5.6%

2025. g. 13. maijs 21:15 UTC

Peļņas

Nu Holdings 1Q Rev $3.2B >NU

2025. g. 13. maijs 21:03 UTC

Top Ziņas

GOP Mega Bill's Details Are Out. Now the Fighting Begins. -- WSJ

2025. g. 13. maijs 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 13. maijs 20:32 UTC

Peļņas

Alcon Raises 2025 View To Sales $10.4B-$10.5B >ALC.EB

2025. g. 13. maijs 20:31 UTC

Peļņas

Alcon 1Q Sales $2.45B >ALC.EB

2025. g. 13. maijs 20:30 UTC

Peļņas

Alcon 1Q Rev $2.47B >ALC.EB

2025. g. 13. maijs 20:30 UTC

Peļņas

Alcon 1Q EPS 70c >ALC.EB

Salīdzinājums

Cenas izmaiņa

Essa Pharma Inc Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

0

Pirkt

0

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

1.7 / 1.72Atbalsts un pretestība

Īstermiņā

Bearish Evidence

Vidējā termiņā

Bullish Evidence

Ilgtermiņā

Weak Bearish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Essa Pharma Inc

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.